[Edaily Reporter Hyera Lee ] In the afternoon session, the KOSPI extended its gains to the 4% range, driven by simultaneous buying from foreign and institutional investors. At one point during the session, the KOSPI’s buy-side circuit breaker was triggered. The KOSDAQ index is also attempting to stabilize its gains after turning bullish.

According to MP Doctor on the 21st, as of 12:42 p.m., the KOSPI was trading at 6,793.73, up 273 points (4.25%) from the previous trading day.
The index opened at 6,553.88, up 0.58%, early in the session. However, shortly after the regular session began, it turned negative and dipped to a low in the 6,440 range. Nevertheless, 35 minutes after the opening, it successfully turned positive again and is now extending its gains.
At 12:41 p.m. today, the buy-side car was triggered once again. This marks the 19th time the buy-side car has been triggered this year. The buy-side car is triggered when the price of the KOSPI 200 futures contract with the highest trading volume on the previous trading day rises by 5% or more and remains at that level for one minute.
By investor type, both foreign investors and institutions have shifted to net buying. Foreign investors have been buying for two consecutive days, with net purchases totaling around 379.6 billion won. Institutions have also turned to net buying for two consecutive days, accumulating over 1.4 trillion won. Retail investors are selling around 1.7933 trillion won worth of shares. Program trading shows a net buying position of 950.1 billion won, combining both arbitrage and non-arbitrage trades.
Most of the top market-cap stocks rebounded from sharp early losses and are now trading in the green.
Among the top 50 stocks by market capitalization, only six are trading lower.
SamsungElectronics(005930) SK hynix(000660), and are up 7.27% and 6.52%, respectively. In addition, , , , , , , and are all rising. is the only stock in the top 10 that is currently down. SKSQUARE(402340) SamsungElectroMechanics(009150) HyundaiMotor(005380) SAMSUNG BIOLOGICS(207940) Samsung Life Insurance(032830) KB Financial Group(105560) KIA CORPORATION(000270) LG Energy Solution(373220)
SAMSUNG BIOLOGICS announced yesterday that it has decided to acquire Poly Peptide, a Swiss contract development and manufacturing organization (CDMO) specializing in peptides, for 2.7 trillion won. The stock is up by around 4% on expectations that the company will make a full-scale entry into the global CDMO market for obesity treatments.
At the same time, SAMSUNG C&T CORPORATION(028260)is trading at 345,000 won, up 8.66%. SAMSUNG C&T CORPORATION holds a 43.06% stake in SAMSUNG BIOLOGICS.
By stock, 547 were up, 338 were down, and 38 were unchanged at the same time.
At the same time, the KOSDAQ index is at 756.87 points, up 7.25 points (0.97%) from the previous trading day.
The KOSDAQ, which opened slightly higher, slipped into negative territory shortly after the opening bell, much like the KOSPI. It has since managed to turn positive in the afternoon session and is attempting to consolidate its gains.
In the KOSDAQ market, retail investors alone are net buyers of 154.9 billion won. In contrast, foreign investors are net sellers of 133.4 billion won, and institutions are also net sellers by 26.1 billion won.
Most of the top-market-cap stocks on the KOSDAQ have also turned higher.
Among the top 14 stocks by market capitalization, all are rising except for SAM CHUN DANG PHARM CO. LTD(000250) and EO Technics Co., Ltd.(039030).
Rainbow Robotics is trading at 416,000 won, up 10.80% from the previous trading day. As SamsungElectronics established a new organizational unit, the “RX (Robotics Experience) Business Promotion Office,” to focus on its robotics business—a key future growth driver—buying interest is flooding into its robotics subsidiary, Rainbow Robotics. Rainbow Robotics even rose as much as 18% at one point during today’s trading session.
Investor sentiment toward biotech stocks has deteriorated overall after Kolon TissueGene, Inc. announced yesterday that its cell-gene therapy for knee osteoarthritis, “TG-C,” failed to demonstrate efficacy in the initial results of its U.S. Phase 3 clinical trial.
SAM CHUN DANG PHARM CO. LTD plummeted to the daily price limit in just one day. The company had announced the previous day that it had received a Pre-ANDA response from the U.S. Food and Drug Administration (FDA), a consultation process preceding the submission of an Abbreviated New Drug Application (ANDA) for an oral semaglutide generic. This response is a document sent by the FDA after officially reviewing the company’s development strategy and does not imply approval. The Pre-ANDA process is a system through which the FDA consults in advance on development strategies, reference drugs, and bioequivalence test plans prior to the submission of a generic drug application. Following this news, SAM CHUN DANG PHARM CO. LTD closed at the daily price limit the previous day.
On the KOSDAQ, 1,048 stocks rose, 636 fell, and 80 remained unchanged.